Zimmer Biomet launches foot, ankle trauma systems
October 9, 2025
Zimmer Biomet (NYSE: ZBH)+
announced that it launched two new solutions for complex foot and ankle trauma.
Zimmer Biomet (NYSE: ZBH)+
announced that it launched two new solutions for complex foot and ankle trauma.
Researchers at Karolinska Institutet, in collaboration with colleagues in South Africa, have investigated whether tuberculosis can be traced in exhaled air. The results, published in Open Forum Infectious Diseases, show that a new method may help identify people with infectious tuberculosis directly in primary care.
Researchers have refined a powerful DNA sequencing tool that can uncover hidden mutations that occur naturally in our bodies as we age. In the largest study to date, they have used the tool to provide insights into the earliest steps of cancer development and the role of mutations in healthy tissue.
UCLA scientists, together with a team of international collaborators, have identified a promising new treatment strategy that can detect, kill and reprogram aggressive, treatment-resistant tumors like osteosarcomas and glioblastoma.
SAN FRANCISCO, Oct. 8, 2025 /PRNewswire/ — Bunkerhill Health today announced that it has received U.S. Food and Drug Administration (FDA) clearance for Bunkerhill MAC, the first artificial intelligence algorithm to detect and quantify mitral annular calcification (MAC). The algorithm runs on routine, non-gated chest CT scans.
BOERNE, Texas, Oct. 8, 2025 /PRNewswire/ — Building once again on their first mover position as a leader in endovascular hemorrhage control and resuscitation, Prytime Medical Devices, Inc. (Prytime) this week announced a new FDA 510(k) clearance for their flagship pREBOA-PRO™ Catheter.
JERSEY CITY, N.J. and OR YEHUDA, Israel, Oct. 8, 2025 /PRNewswire/ — Synchrony Medical, a medical technology company dedicated to transforming respiratory care, announced today the launch of its LibAirty™ Airway Clearance System in the United States. The launch marks an important step forward for people living with chronic lung disease, providing access to advanced at-home therapy designed to improve daily breathing, reduce exacerbations and hospitalizations, and enhance quality of life.
When the Norwegian company that manufactures the Safeback SBX device, which is already on the market, approached Eurac Research to have it independently tested, it was clear that the international research team led by physician and researcher Giacomo Strapazzon would publish the results of the study in any case, regardless of the outcome.
At 47 years of age, Emi Bossio was feeling good about where she was. She had a successful law practice, two growing children and good health. Then she developed a nagging cough. The diagnosis to come would take her breath away.
A new study identifies genetic modifications that make these immune cells, known as CAR-NK cells, more effective at destroying cancer cells.